The Enterprise Value as of December 2024 (TTM) for Cassava Sciences, Inc. (SAVA) is -33031695.00

According to Cassava Sciences, Inc.’s latest financial reports and current stock price. The company's current Enterprise Value is -33031695.00. This represents a change of -104.14% compared to the average of 798.35M of the last 4 quarters.

Cassava Sciences, Inc. (SAVA) Historical Enterprise Value (quarterly & annually)

How has SAVA Enterprise Value performed in the past?

The mean historical Enterprise Value of Cassava Sciences, Inc. over the last ten years is 356.29M. The current -33031695.00 Enterprise Value has changed -1027.09% with respect to the historical average. Over the past ten years (40 quarters), SAVA's Enterprise Value was at its highest in in the June 2021 quarter at 3.14B. The Enterprise Value was at its lowest in in the September 2018 quarter at -8365410.00.

Cassava Sciences, Inc. (SAVA) Enterprise Value by Quarter and Year

Discovering the peaks and valleys of Cassava Sciences, Inc. Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Cassava Sciences, Inc. (SAVA) Average Enterprise Value

How has SAVA Enterprise Value performed in the past?

The current Enterprise Value of Cassava Sciences, Inc. (SAVA) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages

Cassava Sciences, Inc. (SAVA) Enterprise Value vs. Peers

How is SAVA’s Enterprise Value compared to its peers?

Cassava Sciences, Inc.’s Enterprise Value is less than Annovis Bio, Inc. (48.90M), less than Axsome Therapeutics, Inc. (4.08B), less than Reviva Pharmaceuticals Holdings, Inc. (70.91M), less than Seres Therapeutics, Inc. (191.57M), less than Anavex Life Sciences Corp. (809.26M), less than INmune Bio, Inc. (70.25M), less than BioVie Inc. (20.30M), less than Cognition Therapeutics, Inc. (4.08M), less than CureVac N.V. (127.53M), less than Reata Pharmaceuticals, Inc. (6.64B), less than Krystal Biotech, Inc. (4.25B), less than Vir Biotechnology, Inc. (955.33M), less than Propanc Biopharma, Inc. (1.33M), less than Exelixis, Inc. (9.50B), less than TG Therapeutics, Inc. (5.08B), less than Viking Therapeutics, Inc. (4.67B), less than Madrigal Pharmaceuticals, Inc. (6.67B), less than BioXcel Therapeutics, Inc. (81.77M),

Build a custom stock screener for Cassava Sciences, Inc. (SAVA) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Cassava Sciences, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Cassava Sciences, Inc. (SAVA) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Cassava Sciences, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.